ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,147.81
-0.98%
Dow Jones
38,747.42
-0.31%
Gold vs US Dollar
2,315.11
0.23%
Brent Oil
81.635
-0.17%
Bitcoin
67,296.78
-3.18%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AngioDynamics Inc (ANGO)

  7. AngioDynamics Inc (ANGO) News

AngioDynamics (ANGO)

AngioDynamics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ANGO
DateTimeSourceHeadlineSymbolCompany
21/05/202422:30Business WireAngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ SystemNASDAQ:ANGOAngioDynamics Inc
06/05/202421:45Business WireAngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific SessionsNASDAQ:ANGOAngioDynamics Inc
04/04/202412:31IH Market NewsUS Index Futures Rise, Oil Dips SlightlyNASDAQ:ANGOAngioDynamics Inc
04/04/202412:00Business WireAngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset DivestitureNASDAQ:ANGOAngioDynamics Inc
04/04/202411:45Business WireAngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PENASDAQ:ANGOAngioDynamics Inc
01/04/202422:26Business WireAngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.NASDAQ:ANGOAngioDynamics Inc
19/03/202420:01Business WireAngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024NASDAQ:ANGOAngioDynamics Inc
06/03/202421:01Business WireAngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services ConferenceNASDAQ:ANGOAngioDynamics Inc
05/03/202401:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANGOAngioDynamics Inc
15/02/202421:05Business WireAngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 MillionNASDAQ:ANGOAngioDynamics Inc
23/01/202421:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGOAngioDynamics Inc
23/01/202413:00Business WireAngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial DiseaseNASDAQ:ANGOAngioDynamics Inc
22/01/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
11/01/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
08/01/202421:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGOAngioDynamics Inc
05/01/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
05/01/202412:00Business WireAngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 GuidanceNASDAQ:ANGOAngioDynamics Inc
21/12/202321:01Business WireAngioDynamics to Present at the J.P. Morgan Healthcare ConferenceNASDAQ:ANGOAngioDynamics Inc
07/12/202321:01Business WireAngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024NASDAQ:ANGOAngioDynamics Inc
07/12/202313:00Business WireAngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary EmbolismNASDAQ:ANGOAngioDynamics Inc
07/11/202313:03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ANGOAngioDynamics Inc
06/10/202319:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANGOAngioDynamics Inc
05/10/202322:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANGOAngioDynamics Inc
04/10/202312:22IH Market NewsWednesday’s Wall Street Highlights: Apple, Intel, Cal-Maine, A10 Networks, and moreNASDAQ:ANGOAngioDynamics Inc
04/10/202312:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANGOAngioDynamics Inc
04/10/202312:00Business WireAngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 GuidanceNASDAQ:ANGOAngioDynamics Inc
22/09/202302:28Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202302:23Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202302:17Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
22/09/202302:12Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANGOAngioDynamics Inc
 Showing the most relevant articles for your search:NASDAQ:ANGO

Your Recent History

LSE
VAST
Vast Resources
LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
HE1
Helium One Global
LSE
POS
Plexus
LSE
THG
Thg
LSE
EUA
Eurasia Mining
LSE
GCM
Gcm Resources
LSE
GKP
Gulf Keystone Petroleum
LSE
AAU
Ariana Resources
LSE
AFC
Afc Energy
LSE
MIN
Minoan
LSE
LLOY
Lloyds Banking
LSE
GOLD
LSE
BOOT
Boot (henry)
LSE
TERN
Tern
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved